Merck and Eisai present results from Phase 3 LEAP-002 Trial evaluating KEYTRUDA
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
The plant is a dedicated for manufacturing of Mouth dissolving strip.
The OAI classification implies that the USFDA expects further corrective actions and may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved
NCDC branches in States/UTs will provide a boost to Public Health Infrastructurewith prompt surveillance, rapid detection and timely monitoring of diseases enabling Early Interventions
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
The observations primarily relate to the need for improving strategies for microbial control, enhancing quality oversight, augmenting the use of software applications & computerized tools
This dense phase often resembles liquid droplets exhibiting higher protein density and weaker molecular motion than the surrounding medium.
Dr. Pedrocchi is currently an Independent Strategic Advisor and Non-Executive Director to private and public healthcare companies.
New mass spectrometry instrument and consumables launch during IMSC 2022
Subscribe To Our Newsletter & Stay Updated